<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00795574</url>
  </required_header>
  <id_info>
    <org_study_id>HS2006</org_study_id>
    <nct_id>NCT00795574</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety and Efficacy of Infliximab to Treat Hidradenitis Suppurtativa</brief_title>
  <acronym>HS2006</acronym>
  <official_title>Phase 2 Study to Assess the Safety and Efficacy of Infliximab for the Treatment of Hidradenitis Suppurativa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Florida Academic Dermatology Centers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Florida Academic Dermatology Centers</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to assess the safety and efficacy of the IV drug infliximab for the treatment of
      hidradenitis suppurativa
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Hidradenitis Suppurativa</condition>
  <arm_group>
    <arm_group_label>infliximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double blind placebo cross-over</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Double blind placebo controlled cross-over</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>infliximab</intervention_name>
    <description>Dosing is 5mgs/kg at weeks 0,2 and 6 to complete loading dose of drug and then every 8 weeks thereafter until end of treatment phase.</description>
    <arm_group_label>infliximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>5mgs /kg given IV over a minimum of 2 hours at weeks 0,2 and 6 to complete loading dose and then every 8 weeks during maintenance treatment period.</description>
    <arm_group_label>infliximab</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Person must have moderate to severe Hidradenitis suppurativa

          -  Multiple ER or doctors visits related to HS

          -  Intralesional kenalog injection &gt;5/year, but none within 3 months of entry

          -  HS &gt;1 year duration

          -  Failed systemic retinoids, but not within 3 months of entry

          -  Failed at least one prior course of antibiotic therapy, which must not have been
             administered within 3 months of entry to the study (excluding the recommended
             antibiotic regimen given immediately before randomization for evidence of active
             infection

          -  History of surgery (reconstructive), but not within 3 months of entry

        Exclusion Criteria:

          -  Women who are pregnant, nursing, or planning pregnancy within 6 months after the last
             infusion (this includes father's who plan on fathering a child within 6 months after
             their last infusion

          -  Known allergy against infliximab

          -  Use of other systemic anti-inflammatory medication except NSAIDs and low dose systemic
             steroids (equal or less than 10 mg daily prednisolone or equivalent).

          -  Have had any previous treatment with monoclonal antibodies or antibody fragments.

          -  Have a known history of serious infections (eg, hepatitis, pneumonia or
             pyelonephritis) in the previous 3 months.

          -  Have or have had an opportunistic infection (eg, herpes zoster [shingles],
             cytomegalovirus, Pneumocystis carinii, aspergillosis, histoplasmosis, or mycobacteria
             other than TB) within 6 months prior to screening.

          -  Are considered ineligible according to the TB eligibility assessment, screening, and
             early detection of reactivation rules defined in Section 26 on: Tuberculosis
             Eligibility Assessment, Screening, and Early Detection of Reactivation Rules.

          -  Have a history of lymphoproliferative disease, including lymphoma or signs suggestive
             of possible lymphoproliferative disease such as lymphadenopathy of unusual size or
             location (eg, nodes in the posterior triangle of the neck, infraclavicular,
             epitrochlear, or periaortic area), or splenomegaly.

          -  Currently have any known malignancy or have a history of malignancy within the
             previous 5 years, with the exception of basal cell or squamous cell carcinoma of the
             skin that has been fully excised with no evidence of recurrence.

          -  Have current signs or symptoms of severe, progressive or uncontrolled renal, hepatic,
             hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, or cerebral
             disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco A Kerdel, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Florida Acadecmic Dermatology Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Florida Academic Dermatology Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2008</study_first_submitted>
  <study_first_submitted_qc>November 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2008</study_first_posted>
  <last_update_submitted>November 21, 2008</last_update_submitted>
  <last_update_submitted_qc>November 21, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 24, 2008</last_update_posted>
  <responsible_party>
    <name_title>Francisco A Kerdel,M.D.</name_title>
    <organization>Florida Academic Dermatology Centers</organization>
  </responsible_party>
  <keyword>Hidradenitis Suppurativa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hidradenitis</mesh_term>
    <mesh_term>Hidradenitis Suppurativa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

